Conservative Versus Radical Therapy of Prostate Cancer: How Have Recent Advances in Molecular Markers and Imaging Enhanced Our Ability to Prognosticate Risk?

Seminars in Oncology

Volumn 30, Issue 5, 2003, Pages 587-595

  Bagnall, Scott ^a   Klotz, Laurence ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; CAPROMAB PENDETIDE IN 111; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN; TISSUE KALLIKREIN; TUMOR MARKER;

CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; INTERMETHOD COMPARISON; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0142062894     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00348-8     Document Type: Article

References (94)

1. Johansson J, Adami H, Andersson S: High 10 year survival rate in patients with early, untreated prostatic cancer. JAMA 267:2191-2196, 1992
2. Johansson J, Johansson LH: Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277:467-471, 1997
3. Hanash K, Utz DC, Cook EN: Carcinoma of the prostate: A 15 year followup. J Urol 107:450-453, 1972
4. Cook G, Watson FR: Twenty nodules of prostate cancer not treated by total prostatecotmy. J Urol 100:672-674, 1968
5. Barnes R, Hirst A, Rosenquist R: Early carcinoma of the prostate: Comparison of stages A and B. J Urol 115:404-405, 1976
6. Lerner S, Seale-Hawkins C, Carlton CE, et al: The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 146:1040-1045, 1991
7. Handley R, Carr TW, Travis D, et al: Deferred treatment for prostate cancer. Br I Urol 62:249-253, 1988
8. Adolfsson J, Cartensen J, Lowhagen T: Deferred treatment in clinically localized prostate carcinoma. Br J Urol 69:183-187, 1992
9. Lu-Yao GL, Yao SL: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 349:906-910, 1997
10. Holmberg L, Bill-Axelson A, Helgesen F, et al: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781-789, 2002
11. Waaler G, Stenwig AE: Prognosis of localised prostatic cancer managed by "watch and wait" policy. Br I Urol 72:214-219, 1993
12. Whitmore W, Waarner IA, Thompson IM: Expectant management of localized prostatic cancer. Cancer 67:1091-1096, 1991
13. George N: Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet 1:494-496, 1988
14. Aus G, Hugosson I, Norlen L: Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 154:460-465, 1995
15. Sandblom G, Dufmats M, Varenhorst E: Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology 56:442-447, 2000
16. Madsen P, Graversen PH, Gasser TC, et al: Treatment of localized prostatic cancer. Radical prostatectomy versus placebo: A 15-year follow-up. Scand J Urol Nephrol 110:95-100, 1988 (suppl)
17. Leek J, Lench N, Maraj B, et al: Prostate-specific membrane antigen: Evidence for the existence of a second related human gene. Br J Cancer 72:583-588, 1995
18. Su SL, Huang IP, Fair WR, et al: Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression. Cancer Res 55:1441-1443, 1995
19. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927-935, 1987
20. Lopes AD, Davis WL, Rosenstraus MJ, et al: Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 50:6423-6429, 1990
21. Murphy GP, Elgamal AA, Su SL, et al: Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 83:2259-2269, 1998
22. Kawakami M, Nakayama J: Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 57:2321-2324, 1997
23. Moreno JG, Croce CM, Fischer R, et al: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52:6110-6112, 1992
24. Grauer LS, Lawler KD, Marignac JL, et al: Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM′ protein in the LNCaP prostatic carcinoma cell line. Cancer Res 58:4787-4789, 1998
25. Murphy GP, Greene TG, Tino WT, et al: Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urol 160:2396-2401, 1998
26. Kahn D, Williams RD, Manyak MJ, et al: 111 Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 159:2041-2046, 1998
27. Elgamal AA, Troychak MJ, Murphy GP: ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients. Prostate 37:261-269, 1998
28. Zhang S, Zhang HS, Reuter VE, et al: Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 4:295-302, 1998
29. Zhang S, Zhang HS, Cordon-Cardo C, et al: Selection of tumor antigens as targets for immune attack using immunohistochemistry: Protein antigens. Clin Cancer Res 4:2669-2676, 1998
30. Tjoa BA, Simmons SJ, Bowes VA, et al: Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36:39-44, 1998
31. Murphy GP, Tjoa BA, Simmons SJ, et al: Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 43:59-62, 2000
32. Gong MC, Latouche JB, Krause A, et al: Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1:123-127, 1999
33. Renneberg H, Friedetzky A, Konrad L, et al: Prostate specific membrane antigen (PSM) is expressed in various human tissues: Implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread. Urol Res 27:23-27, 1999
34. Israeli RS, Powell CT, Corr JG, et al: Expression of the prostate-specific membrane antigen. Cancer Res 54:1807-1811, 1994
35. Lintula S, Stenman UH: The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol 157:1969-1972, 1997
36. Llanes L, Ferruelo A, Paez A, et al: The clinical utility of the prostate specific membrane antigen reverse-transcription/polymerase chain reaction to detect circulating prostate cells: An analysis in healthy men and women. BJU Int 89:882-885, 2002
37. Hara N, Kasahara T, Kawasaki T, et al: Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: Value for the staging of prostate cancer. Clin Cancer Res 8:1794-1799, 2002
38. Woodrum DL, French CM, Hill TM, et al: Analytical performance of the Tandem-R free PSA immunoassay measuring free prostate-specific antigen. Clin Chem 43:1203-1208, 1997
39. Takayama TK, Fujikawa K, Davie EW: Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 272: 21582-21588, 1997
40. Young CY, Andrews PE, Montgomery BT, et al: Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 31:818-824, 1992
41. Partin AW, Catalona WJ, Finlay JA, et al: Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 54:839-845, 1999
42. Nam RK, Diamandis EP, Toi A, et al: Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 18:1036-1042, 2000
43. Tremblay RR, Deperthes D, Tetu B, et al: Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol 150: 455-459, 1997
44. Darson MF, Pacelli A, Roche P, et al: Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49:857-862, 1997
45. Scorilas A, Plebani M, Mazza S, et al: Serum human glandular kalllikrein and insulin-like growth factor 1 improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and % free PSA. Prostate 54:220-229, 2003
46. Magklara A, Scorilas A, Catalona WJ, et al: The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 45:1960-1966, 1999
47. Yu JX, Chao L, Chao J: Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. J Biol Chem 269: 18843-18848, 1994
48. Takeuchi T, Shuman MA, Craik CS: Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 96:11054-11061, 1999
49. Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al: Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 35:275-368, 1998
50. Dhanasekaran SM, Barrette TR, Ghosh D, et al: Delineation of prognostic biomarkers in prostate cancer. Nature 412:822-826, 2001
51. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34, 1995
52. Rajaram S, Baylink DJ, Mohan S: Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions. Endocr Rev 18:801-831, 1997
53. Rajah R, Katz L, Nunn S, et al: Insulin-like growth factor binding protein (IGFBP) proteases: Functional regulators of cell growth. Prog Growth Factor Res 6:273-284, 1995
54. Baserga R: The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 55:249-252, 1995
55. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566, 1998
56. Bok RA, Small EJ: Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 2:918-926, 2002
57. Poon RT, Fan ST, Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19:1207-1225, 2001
58. Weidner N, Carroll PR, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409, 1993
59. Nelson JB, Hedican SP, George DJ, et al: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1:944-949, 1995
60. Battistini B, D'Orleans-Juste P, Sirois P: Endothelins: Circulating plasma levels and presence in other biologic fluids. Lab Invest 68:600-628, 1993
61. Chang F, Syrjanen S, Syrjanen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13:1009-1022, 1995
62. Meyers FJ, Chi SG, Fishman JR, et al: p53 mutations in benign prostatic hyperplasia. J Natl Cancer Inst 85:1856-1858, 1993
63. Bookstein R, MacGrogan D, Hilsenbeck SG, et al: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369-33673, 1993
64. Dinjens WN, van der Weiden MM, Schroeder FH, et al: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56:630-633, 1994
65. Effert PJ, McCoy RH, Walther PJ, et al: p53 gene alterations in human prostate carcinoma. J Urol 150:257-261, 1993
66. Bauer JJ, Sesterhenn IA, Mostofi FK, et al: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 156:1511-1516, 1996
67. Quinn DI, Henskall SM, Head DR, et al: Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 60: 1585-1594, 2000
68. Huang A, Gandour-Edwards R, Rosenthal SA, et al: p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 51:346-351, 1998
69. Grignon DJ, Caplan R, Sarkar FH, et al: p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610. J Natl Cancer Inst 89:158-165, 1997
70. Brewster SF, Oxley JD, Trivella M, et al:; Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 161:1238-1243, 1999
71. Stackhouse GB, Sesterhenn IA, Bauer JJ, et al: p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 162:2040-2045, 1999
72. Ruijter E, van de Kaa C, Aalders T, et al: Heterogeneous expression of E-cadherin and p53 in prostate cancer: Clinical implications. BIOMED-II Markers for Prostate Cancer Study Group. Mod Pathol 11:276-281, 1998
73. Keshgegian AA, Johnston E, Cnaan A: Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 110:443-449, 1998
74. Bubendorf L, Tapia C, Gasser TC, et al: Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 29:949-954, 1998
75. Umbas R, Schalken JA, Aalders TW, et al: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52:5104-5109, 1992
76. Bussemakers MJ, van Moorselaar RJ, Giroldi LA, et al: Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 52:2916-2922, 1992
77. Kuczyk M, Machtens S, Hradil K, et al: Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer 81:1052-1058, 1999
78. Adusumilli S, Pretorius ES: Magnetic resonance imaging of prostate cancer. Semin Urol Oncol 20:192-210, 2002
79. Outwater EK, Petersen RO, Siegelman ES, et al: Prostate carcinoma: Assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology 193:333-339, 1994
80. Hricak H, White S, Vigneron D, et al: Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology 193:703-709, 1994
81. Yu KK, Scheidler J, Hricak H, et al: Prostate cancer: Prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 213:481-488, 1999
82. Scheidler J, Hricak H, Vigneron DB, et al: Prostate cancer: Localization with three-dimensional proton MR spectroscopic imaging - Clinicopathologic study. Radiology 213: 473-480, 1999
83. Swanson MG, Vigneron DB, Tran TK, et al: Magnetic resonance imaging and spectroscopic imaging of prostate cancer. Cancer Invest 19:510-523, 2001
84. Lu-Yao G, Albertsen PC, Stanford JL, et al: Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325:740, 2002
85. Sakr W, Haas GP, Cassin BF, et al: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150:379-35, 1993
86. Pound C, Partin EAW, Eisenberg MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
87. Kattan M, Zelefsky MJ, Kupelian PA, et al: Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18: 3352-3359, 2000
88. Albertsen P, Hanley IA, Gleason DF, et al: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975-980, 1998
89. Chodak G: The management of localized prostate cancer. J Urol 152:1766-1768, 1994
90. Choo R, DeBoer G, Klotz L, et al: PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 50:615-620, 2001
91. Choo R, Klotz L, Danjoux C, et al: Feasibility study of watchful waiting for localized low to intermediate grade prostate cancer with selective delayed intervention based on PSA, histologic, and/or clinical progression. J Urol 167:1664-1669, 2002
92. Klotz LH, Choo R, Morton G, et al: Expectant management with selective delayed intervention for favorable-risk prostate cancer. Can J Urol 9:2-7, 2002 (suppl 1)
93. Do V, Choo R, DeBoer G, et al: The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. Br J Urol Int 89:703-709, 2002
94. Epstein JI, Walsh PC, Carter HB: Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 166:1688-1691, 2001